# Domantis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/domantis

- Industry: Pharmaceuticals
- Headquarters: Waltham, US
- Website: www.domantis.com
- Total disclosed funding: $62M
- Latest round: Series B (Dec 13, 2005)
- Investors on record: 5

## About

Domantis is a biopharmaceutical company focused on developing domain antibodies and glycan-based therapeutics that enhance therapeutic efficacy and biopharmaceutical applications.Founded in 2000 in Waltham, Massachusetts, Domantis develops innovative biopharmaceutical solutions with a specialization in domain antibodies and glycosylation processes. In January 2007, the company was acquired by GlaxoSmithKline for approximately USD 454 mn, marking a significant milestone in its operations. The company has successfully completed 4 deals to date, showcasing its active engagement in the biopharmaceutical sector.Domantis Ltd. specializes in the development of domain antibodies (dAbs) and glycan-based therapeutics, which are critical in advancing therapeutic efficacy and biopharmaceutical applications. Their core product offerings focus on glycosylation processes, which significantly enhance protein stability, folding, and interactions, particularly in monoclonal antibodies. By leveraging advanced technologies such as glycan mapping and glycoengineering, the company aims to improve therapeutic outcomes in various disease treatment protocols. Domantis serves a diverse clientele, including biopharmaceutical companies and research institutions across North America, Europe, and Asia. These products are designed to meet the growing demand for innovative biotherapeutics, particularly in the fields of oncology and immunology.Domantis Ltd. generates revenue through a B2B model, providing its specialized glycan-based therapeutics and domain antibodies to pharmaceutical and biotech companies engaged in drug development. Transactions typically occur through partnerships and licensing agreements, where clients procure specific products for their research and development needs. These agreements may entail upfront payments combined with royalties based on the sales performance of the resulting therapeutics. While specific pricing details for individual products are proprietary, the company’s flagship offerings, including its patented dAbs and glycoengineering solutions, are positioned to command premium pricing due to their innovative nature and the advanced technology involved in their development. This structured approach allows Domantis to solidify its presence in the competitive biopharmaceutical market.Domantis plans to utilize the proceeds from its recent acquisition by GlaxoSmithKline, amounting to USD 454 mn, to further enhance its research and development capabilities. The company is focused on designing new products, particularly in the domain of glycan-based therapeutics, with a view to launch in the next few years. Additionally, there are strategic initiatives aimed at expanding into new geographic markets, particularly in Asia and Europe, by 2025, capitalizing on the growing demand for innovative therapies in those regions.

## Funding rounds

- Series B, Dec 13, 2005, $29M — 3i, MC Life Science Ventures, Albany Venture Managers, Novo Nordisk A/S, ISIS
- Series B, Jun 1, 2004, $33M — 3i

## Investors

- 3i (https://capitalatlas.ai/funds/3i) — Series B
- MC Life Science Ventures — Series B
- Albany Venture Managers (https://capitalatlas.ai/funds/albany-venture-managers) — Series B
- Novo Nordisk A/S — Series B
- ISIS — Series B